UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 161

Sortiert nach

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (14), p.4059-4072

2018

Link zum Volltext

Verfügbarkeit prüfen

BCL-2 FAMILY: Regulators of Cell Death

Annual review of immunology, 1998-01, Vol.16 (1), p.395-419

1998

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2021-02, Vol.9 (2), p.e002015

2021

Link zum Volltext

Verfügbarkeit prüfen

Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms

Clinical cancer research, 2010-01, Vol.16 (2), p.497-508

2010

Link zum Volltext

Verfügbarkeit prüfen

BAX-Induced Cell Death May not Require Interleukin 1β -Converting Enzyme-Like Proteases

Proceedings of the National Academy of Sciences - PNAS, 1996-12, Vol.93 (25), p.14559-14563

1996

Link zum Volltext

Verfügbarkeit prüfen

A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo

Journal of translational medicine, 2007-11, Vol.5 (1), p.61-61, Article 61

2007

Link zum Volltext

Verfügbarkeit prüfen

Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb

Journal of cancer research and clinical oncology, 2013-02, Vol.139 (2), p.315-325

2013

Link zum Volltext

Verfügbarkeit prüfen

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Cancer Immunology, Immunotherapy, 2015-01, Vol.64 (1), p.61-73

2015

Link zum Volltext

Verfügbarkeit prüfen

Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity

Molecular cancer therapeutics, 2020-04, Vol.19 (4), p.1040-1051

2020

Link zum Volltext

Verfügbarkeit prüfen

Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR

Frontiers in immunology, 2014, Vol.4, p.505-505

2014

Link zum Volltext

Verfügbarkeit prüfen

Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 Antibodies

Immunological investigations, 2009, Vol.38 (1), p.76-92

2009

Link zum Volltext

Verfügbarkeit prüfen

A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity

Cancer immunology research, 2019-11, Vol.7 (11), p.1864-1875

2019

Link zum Volltext

Verfügbarkeit prüfen

Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model

Journal of neuroimmunology, 2009-07, Vol.212 (1), p.65-73

2009

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells

Cancer research (Chicago, Ill.), 1999-12, Vol.59 (24), p.6109-6112

1999

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5672: Pharmacodynamics and potential predictive biomarkers of ABBV-428, a first-in-class mesothelin (MSLN)-CD40 bispecific, in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5672-5672

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 953: LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.953-953

2018

Link zum Volltext

Verfügbarkeit prüfen

BID: a novel BH3 domain-only death agonist

Genes & development, 1996-11, Vol.10 (22), p.2859-2869

1996

Link zum Volltext

Verfügbarkeit prüfen

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-[alpha] pathways

Cancer immunology, immunotherapy, 2015-01, Vol.64 (1), p.61

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2722: Active recruitment of immune effector cells mediates in vivo tumor growth inhibition by enavatuzumab, an antibody to human TWEAK receptor

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2722-2722

2012

Link zum Volltext

Verfügbarkeit prüfen

TRU-016, An Anti-CD37 SMIP™ Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin's Lymphoma

Blood, 2010-11, Vol.116 (21), p.3931-3931

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract B17: PDL192, a humanized antibody to TweakR exhibits potent antitumor activity in pancreatic cancer models

Clinical cancer research, 2010-07, Vol.16 (14_Supplement), p.B17-B17

2010

Link zum Volltext

Verfügbarkeit prüfen

Bcl-XL and Bcl-2 repress a common pathway of cell death

The Journal of experimental medicine, 1995-09, Vol.182 (3), p.821-828

1995

Link zum Volltext

Verfügbarkeit prüfen

Abstract B231: Targeting Her2+ ductal breast cancer with PDL192, a novel humanized anti-TweakR monoclonal antibody

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.B231-B231

2009

Link zum Volltext

Verfügbarkeit prüfen

A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo

Journal of translational medicine, 2007-11, Vol.5, p.61-61

2007

Link zum Volltext

Verfügbarkeit prüfen

BAX-induced cell death may not require interleukin 1beta-converting enzyme-like proteases

Proceedings of the National Academy of Sciences - PNAS, 1996-12, Vol.93 (25), p.14559

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 161

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(141)

Publikationsform

Sprache

Englisch
(161)
Japanisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates

BCL-2 FAMILY: Regulators of Cell Death

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms

BAX-Induced Cell Death May not Require Interleukin 1β -Converting Enzyme-Like Proteases

A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo

Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity

Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR

Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 Antibodies

A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity

Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model

Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells

Abstract 5672: Pharmacodynamics and potential predictive biomarkers of ABBV-428, a first-in-class mesothelin (MSLN)-CD40 bispecific, in patients with advanced solid tumors

Abstract 953: LRRC15 is a novel antigen in sarcoma and the therapeutic target of the antibody-drug conjugate (ADC) ABBV-085

BID: a novel BH3 domain-only death agonist

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-[alpha] pathways

Abstract 2722: Active recruitment of immune effector cells mediates in vivo tumor growth inhibition by enavatuzumab, an antibody to human TWEAK receptor

TRU-016, An Anti-CD37 SMIP™ Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin's Lymphoma

Abstract B17: PDL192, a humanized antibody to TweakR exhibits potent antitumor activity in pancreatic cancer models

Bcl-XL and Bcl-2 repress a common pathway of cell death

Abstract B231: Targeting Her2+ ductal breast cancer with PDL192, a novel humanized anti-TweakR monoclonal antibody

A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo

BAX-induced cell death may not require interleukin 1beta-converting enzyme-like proteases

Suchergebnisse filtern